Literature DB >> 17608748

Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice.

I Grossmann1, G H de Bock, C J H van de Velde, J Kievit, T Wiggers.   

Abstract

OBJECTIVE: Follow-up after curative resection of colorectal carcinoma (CRC) has been subjected to debate concerning its effectiveness to reduce cancer mortality. Current national and international guidelines advise CEA measurements every 3 months during 3 years after surgery. The common clinical practice and opinion about follow-up for colorectal carcinoma, was evaluated by means of a survey among Dutch general surgeons.
METHOD: A web-based survey of follow-up after treatment of CRC was sent to all registered Dutch general surgeons. A reply from 246 surgeons treating patients for colorectal carcinoma in 105 out of 118 hospitals was received (response rate 91%). Questions related to actual follow-up protocol, opinion about serum CEA monitoring, liver and/or lung metastasectomy, and motivation to participate in a new trial concerning follow-up.
RESULTS: For the majority of surgeons the length of follow-up was influenced by age of the patient (62%) and physical condition (76%) prohibiting hepatic metastasectomy. The generally accepted follow-up protocol consisted of CEA measurements every 3 months in the first year and six-monthly thereafter, and ultrasound examination of the liver every 6 months. Nearly all surgeons (92%) were willing to participate in a new study of follow-up protocol.
CONCLUSION: The adherence to national guidelines for the follow-up of colorectal carcinoma is low. The indistinctness about follow-up after curative treatment of colorectal carcinoma also affects clinical practice. Recent advancements in imaging techniques, liver and lung surgery have changed circumstances, which are not yet anticipated upon in current guidelines. Renewal of follow-up based upon scientific evidence is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608748     DOI: 10.1111/j.1463-1318.2007.01303.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  12 in total

1.  Surveillance after curative resection of colorectal cancer.

Authors:  Adena Scheer; Rebecca Ann C Auer
Journal:  Clin Colon Rectal Surg       Date:  2009-11

2.  Estimating the cost related to surveillance of colorectal cancer in a French population.

Authors:  Catherine Lejeune; Christine Binquet; Franck Bonnetain; Amel Mahboubi; Michal Abrahamowicz; Thierry Moreau; Maria Raikou; Laurent Bedenne; Catherine Quantin; Claire Bonithon-Kopp
Journal:  Eur J Health Econ       Date:  2009-03-04

3.  Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists.

Authors:  Hidde J Braam; Djamila Boerma; Marinus J Wiezer; Bert van Ramshorst
Journal:  Int J Clin Oncol       Date:  2015-03-19       Impact factor: 3.402

4.  Large variation between hospitals in follow-up for colorectal cancer in southern Netherlands.

Authors:  L N van Steenbergen; I H J T de Hingh; H J T Rutten; M C M Rijk; R G Orsini; J W W Coebergh; V E P P Lemmens
Journal:  Int J Colorectal Dis       Date:  2013-04-28       Impact factor: 2.571

Review 5.  Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Authors:  Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2013-07-19       Impact factor: 3.201

6.  Hydroxylated collagen peptide in urine as biomarker for detecting colorectal liver metastases.

Authors:  Zarina S Lalmahomed; Mirelle Ee Bröker; Nick A van Huizen; Robert R J Coebergh van den Braak; Lennard Jm Dekker; Dimitris Rizopoulos; Cornelis Verhoef; Ewout W Steyerberg; Theo M Luider; Jan Nm IJzermans
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

7.  Concordance with ASCO guidelines for surveillance after colorectal cancer treatment: a population-based analysis.

Authors:  Jeffrey J Sisler; Bosu Seo; Alan Katz; Emma Shu; Daniel Chateau; Piotr Czaykowski; Debrah Wirtzfeld; Harminder Singh; Donna Turner; Patricia Martens
Journal:  J Oncol Pract       Date:  2012-01-31       Impact factor: 3.840

8.  Evaluation of the use of decision-support software in carcino-embryonic antigen (CEA)-based follow-up of patients with colorectal cancer.

Authors:  Charlotte J Verberne; Cornelis H Nijboer; Geertruida H de Bock; Irene Grossmann; Theo Wiggers; Klaas Havenga
Journal:  BMC Med Inform Decis Mak       Date:  2012-03-05       Impact factor: 2.796

9.  Differing Serum Cea in Primary and Recurrent Rectal Cancer - A Reflection of Histology?

Authors:  Angela C Chang; Leigh R Warren; Savio G Barreto; Randolph Williams
Journal:  World J Oncol       Date:  2012-04-23

10.  The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper.

Authors:  Irene Grossmann; Charlotte Verberne; Geertruida De Bock; Klaas Havenga; Ido Kema; Joost Klaase; Andrew Renehan; Theo Wiggers
Journal:  Cancers (Basel)       Date:  2011-05-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.